SIGA TECHNOLOGIES INC (SIGA) Stock Price & Overview

NASDAQ:SIGA • US8269171067

5.47 USD
0 (-0.09%)
At close: Mar 12, 2026
5.47 USD
0 (0%)
After Hours: 3/12/2026, 8:10:42 PM

The current stock price of SIGA is 5.47 USD. Today SIGA is down by -0.09%. In the past month the price decreased by -17.62%. In the past year, price decreased by -1.97%.

SIGA Key Statistics

52-Week Range4.95 - 9.62
Current SIGA stock price positioned within its 52-week range.
1-Month Range5.11 - 7.02
Current SIGA stock price positioned within its 1-month range.
Market Cap
391.707M
P/E
17.65
Fwd P/E
3.53
EPS (TTM)
0.31
Dividend Yield
10.96%

SIGA Stock Performance

Today
-0.09%
1 Week
-12.34%
1 Month
-17.62%
3 Months
-15.33%
Longer-term
6 Months -38.68%
1 Year -1.97%
2 Years -36.10%
3 Years -4.87%
5 Years -15.85%
10 Years N/A

SIGA Stock Chart

SIGA TECHNOLOGIES INC / SIGA Daily stock chart

SIGA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to SIGA. When comparing the yearly performance of all stocks, SIGA is a bad performer in the overall market: 75.38% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
SIGA Full Technical Analysis Report

SIGA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to SIGA. SIGA gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SIGA Full Fundamental Analysis Report

SIGA Earnings

On March 10, 2026 SIGA reported an EPS of -0.08 and a revenue of 3.79M.

Next Earnings DateMay 6, 2026
Last Earnings DateMar 10, 2026
PeriodQ4 / 2025
EPS Reported-$0.08
Revenue Reported3.79M
EPS Surprise %
Revenue Surprise %
SIGA Earnings History

SIGA Forecast & Estimates

For the next year, analysts expect an EPS growth of 400.13% and a revenue growth 132.36% for SIGA


Analysts
Analysts0
Price TargetN/A
EPS Next Y400.13%
Revenue Next Year132.36%
SIGA Forecast & Estimates

SIGA Groups

Sector & Classification

SIGA Financial Highlights

Over the last trailing twelve months SIGA reported a non-GAAP Earnings per Share(EPS) of 0.31. The EPS decreased by -62.2% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)74.71M
Industry RankSector Rank
PM (TTM) 43.37%
ROA 32.26%
ROE 36.72%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-112.7%
Sales Q2Q%-95.34%
EPS 1Y (TTM)-62.2%
Revenue 1Y (TTM)N/A
SIGA financials

SIGA Ownership

Ownership
Inst Owners52%
Shares71.61M
Float40.57M
Ins Owners8.93%
Short Float %8.22%
Short Ratio8.79
SIGA Ownership

SIGA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO27.96943.209B
JNJ JOHNSON & JOHNSON20.78585.582B
MRK MERCK & CO. INC.22.4287.316B
PFE PFIZER INC9155.235B
BMY BRISTOL-MYERS SQUIBB CO9.31122.147B
ZTS ZOETIS INC16.3150.567B
RPRX ROYALTY PHARMA PLC- CL A8.8826.934B
VTRS VIATRIS INC5.516.085B
ELAN ELANCO ANIMAL HEALTH INC21.5611.659B
AXSM AXSOME THERAPEUTICS INC N/A8.158B
BLTE BELITE BIO INC - ADR N/A6.518B
TERN TERNS PHARMACEUTICALS INC N/A4.968B
LGND LIGAND PHARMACEUTICALS24.914.412B

About SIGA

Company Profile

SIGA logo image SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

Company Info

IPO: 1997-09-09

SIGA TECHNOLOGIES INC

31 East 62Nd Street

New York City NEW YORK 10065 US

CEO: Phillip L. Gomez

Employees: 46

SIGA Company Website

SIGA Investor Relations

Phone: 12126729100

SIGA TECHNOLOGIES INC / SIGA FAQ

Can you describe the business of SIGA TECHNOLOGIES INC?

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.


Can you provide the latest stock price for SIGA TECHNOLOGIES INC?

The current stock price of SIGA is 5.47 USD. The price decreased by -0.09% in the last trading session.


Does SIGA TECHNOLOGIES INC pay dividends?

SIGA TECHNOLOGIES INC (SIGA) has a dividend yield of 10.96%. The yearly dividend amount is currently 0.6.


How is the ChartMill rating for SIGA TECHNOLOGIES INC?

SIGA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the GICS sector and industry of SIGA stock?

SIGA TECHNOLOGIES INC (SIGA) operates in the Health Care sector and the Pharmaceuticals industry.


How many employees does SIGA TECHNOLOGIES INC have?

SIGA TECHNOLOGIES INC (SIGA) currently has 46 employees.


Can you provide the market cap for SIGA TECHNOLOGIES INC?

SIGA TECHNOLOGIES INC (SIGA) has a market capitalization of 391.71M USD. This makes SIGA a Small Cap stock.